Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 207 Published: April 29, 2022 Report Code: GMDGDHC22134IDB

Diabetic Nephropathy pipeline market research report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Key Targets in the Diabetic Nephropathy Pipeline Market

In the Diabetic Nephropathy pipeline market, the key targets are Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2. Cannabinoid Receptor 1 has the highest pipeline products.

Diabetic Nephropathy Pipeline Market, by Targets

Diabetic Nephropathy Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Diabetic Nephropathy Pipeline Market

The key MoA in the Diabetic Nephropathy pipeline market are Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist. Cannabinoid Receptor 1 Antagonist has the highest pipeline products.

Diabetic Nephropathy Pipeline Market, by MoA

Diabetic Nephropathy Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Diabetic Nephropathy Pipeline Market

The key RoA in the Diabetic Nephropathy pipeline market are oral, intravenous, subcutaneous, parenteral, topical, intraarterial, intravitreal, nasogastric, and ophthalmic. Oral has the highest pipeline products.

Diabetic Nephropathy Pipeline Market, by RoA

Diabetic Nephropathy Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Diabetic Nephropathy Pipeline Market

In the Diabetic Nephropathy pipeline market, the key molecule types are small molecule, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, antisense oligonucleotide, biologic, antisense RNAi oligonucleotide, peptide, recombinant peptide, and recombinant protein. Small molecule has the highest pipeline products.

Diabetic Nephropathy Pipeline Market, by Molecule Types

Diabetic Nephropathy Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Diabetic Nephropathy Pipeline Market

The key companies in the Diabetic Nephropathy pipeline market are AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc. AstraZeneca Plc has the highest number of pipeline products.

Diabetic Nephropathy Pipeline Market, by Companies

Diabetic Nephropathy Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Cannabinoid Receptor 1, Nuclear Factor Erythroid 2 Related Factor 2, Endothelin 1 Receptor, Sodium/Glucose Cotransporter 2, Transforming Growth Factor Beta 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, and C-C Chemokine Receptor Type 2
Key MoA Cannabinoid Receptor 1 Antagonist, Endothelin 1 Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Sodium/Glucose Cotransporter 2 Inhibitor, Transforming Growth Factor Beta 1 Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, and C-C Chemokine Receptor Type 2 Antagonist
Key RoA Oral, Intravenous, Subcutaneous, Parenteral, Topical, Intraarterial, Intravitreal, Nasogastric, and Ophthalmic
Key molecule types Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Fusion Protein, Antisense Oligonucleotide, Biologic, Antisense RNAi Oligonucleotide, Peptide, Recombinant Peptide, and Recombinant Protein
Key companies AstraZeneca Plc, Boehringer Ingelheim International GmbH, Goldfinch Bio Inc, Scohia Pharma Inc, Serodus ASA, ZyVersa Therapeutics Inc, and Aadi Bioscience Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • Aadi Bioscience Inc

    AIBIOS Co Ltd

    Akebia Therapeutics Inc

    Algomedix Inc

    Anagenics Ltd

    APT Therapeutics Inc

    AptaBio Therapeutics Inc

    Araim Pharmaceuticals Inc

    Astellas Pharma Inc

    AstraZeneca Plc

    Bayer AG

    Betagenon AB

    Bird Rock Bio Inc

    BLR Bio LLC

    Boehringer Ingelheim International GmbH

    Bristol-Myers Squibb Co

    Caladrius Biosciences Inc

    CCRP Therapeutics GmbH

    Certa Therapeutics Pty Ltd

    ChemoCentryx Inc

    Chinook Therapeutics Inc

    Corbus Pharmaceuticals Inc

    CSL Ltd

    Curacle Co Ltd

    Daiichi Sankyo Co Ltd

    DiaMedica Therapeutics Inc

    Dimerix Ltd

    Frontbio Co Ltd

    Future Medicine Co Ltd

    GenKyoTex SA

    Gilead Sciences Inc

    Glycadia Inc

    Gmax Biopharm LLC

    GNI Group Ltd

    Goldfinch Bio Inc

    Guangdong East Sunshine Pharmaceutical Co Ltd

    Guangzhou Magpie Pharmaceutical Co Ltd

    Guangzhou Nanxin Pharmaceutical Co Ltd

    Hua Medicine Shanghai Ltd

    Inovio Pharmaceuticals Inc

    InSilico Medicine

    Inversago Pharma Inc

    Johnson & Johnson

    Landos Biopharma Inc

    MediPost Co Ltd

    Merck & Co Inc

    Mesoblast Ltd

    Mitsubishi Tanabe Pharma Corp

    Nanjing Aimeifei Biomedical Technology Co Ltd

    Novartis AG

    Novo Nordisk AS

    Ono Pharmaceutical Co Ltd

    Orbsen Therapeutics Ltd

    PhytoHealth Corp

    Poxel SA

    Praetego Inc

    ProKidney LLC

    RAGE Biotech Pty Ltd

    Reata Pharmaceuticals Inc

    Rebus Holdings Inc

    Scohia Pharma Inc

    Secarna Pharmaceuticals GmbH & Co KG

    Serodus ASA

    Shanghai Alebund Pharmaceuticals Ltd

    Shanghai Pharmaceutical Group Co Ltd

    siRNAgen Therapeutics Corp

    Slate Bio Inc

    Sulfateq BV

    Unicyte AG

    Vidasym Inc

    Wuhan Hamilton Bio-technology Co Ltd

    Wuhan LL Science and Technology Development Co Ltd

    XORTX Therapeutics Inc

    ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Nephropathy – Overview

Diabetic Nephropathy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Nephropathy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Nephropathy – Companies Involved in Therapeutics Development

Diabetic Nephropathy – Drug Profiles

Diabetic Nephropathy – Dormant Projects

Diabetic Nephropathy – Discontinued Products

Diabetic Nephropathy – Product Development Milestones

Featured News & Press Releases

Feb 28, 2022: Goldfinch Bio announces positive preliminary data from phase 2 clinical trial evaluating GFB-887 as a precision medicine for patients with focal segmental glomerular sclerosis (FSGS)

Nov 08, 2021: Goldfinch Bio showcases biology, genetic and clinical programs at ASN Kidney Week demonstrating leadership in precision medicines for kidney diseases

Sep 17, 2021: adMare Portfolio Company, Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 Blocker

Sep 07, 2021: Inversago Pharma initiates a phase 1 clinical trial on INV-202, a next generation peripherally-acting CB1 blocker

Sep 01, 2021: XORTX announces grant of European patent supporting diabetic nephropathy

Aug 28, 2021: Bayer announces KERENDIA (finerenone) reduces the risk of cardiovascular outcomes in new phase III FIGARO-DKD study in adults with chronic kidney disease (Stages 1-4) associated with type 2 diabetes

Aug 17, 2021: Bayer to present late breaking data from Phase III FIGARO-DKD (finerenone) studies

Aug 02, 2021: Shanghai Pharmaceuticals SPH3127 tablets new indications received phase II clinical trial approval notice

Jul 27, 2021: Goldfinch Bio announces upcoming presentations at the 13th International Podocyte Conference

Jun 22, 2021: Caladrius Biosciences to assess its CLBS201 CD34+ cell therapy in diabetic kidney disease

May 13, 2021: Goldfinch Bio initiates phase 1 clinical trial of GFB-024, a novel precision medicine product candidate for patients with severe insulin resistant Diabetic Nephropathy (DN)

Mar 31, 2021: Mitsubishi Tanabe Pharma wins patent infringement lawsuit of Canagliflozin Hydrate in the U.S. district court

Feb 26, 2021: Canagliflozin (TA-7284) has been approved in Taiwan for diabetic nephropathy

Sep 21, 2020: New study offers hope for patients with diabetes and advanced kidney disease

Sep 08, 2020: Publication of a preclinical study: SCO-792, an enteropeptidase inhibitor, may be a new therapeutic agent for diabetic kidney disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Diabetic Nephropathy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Diabetic Nephropathy – Pipeline by Aadi Bioscience Inc, 2022

Diabetic Nephropathy – Pipeline by AIBIOS Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Akebia Therapeutics Inc, 2022

Diabetic Nephropathy – Pipeline by Algomedix Inc, 2022

Diabetic Nephropathy – Pipeline by Anagenics Ltd, 2022

Diabetic Nephropathy – Pipeline by APT Therapeutics Inc, 2022

Diabetic Nephropathy – Pipeline by AptaBio Therapeutics Inc, 2022

Diabetic Nephropathy – Pipeline by Araim Pharmaceuticals Inc, 2022

Diabetic Nephropathy – Pipeline by Astellas Pharma Inc, 2022

Diabetic Nephropathy – Pipeline by AstraZeneca Plc, 2022

Diabetic Nephropathy – Pipeline by Bayer AG, 2022

Diabetic Nephropathy – Pipeline by Betagenon AB, 2022

Diabetic Nephropathy – Pipeline by Bird Rock Bio Inc, 2022

Diabetic Nephropathy – Pipeline by BLR Bio LLC, 2022

Diabetic Nephropathy – Pipeline by Boehringer Ingelheim International GmbH, 2022

Diabetic Nephropathy – Pipeline by Bristol-Myers Squibb Co, 2022

Diabetic Nephropathy – Pipeline by Caladrius Biosciences Inc, 2022

Diabetic Nephropathy – Pipeline by CCRP Therapeutics GmbH, 2022

Diabetic Nephropathy – Pipeline by Certa Therapeutics Pty Ltd, 2022

Diabetic Nephropathy – Pipeline by ChemoCentryx Inc, 2022

Diabetic Nephropathy – Pipeline by Chinook Therapeutics Inc, 2022

Diabetic Nephropathy – Pipeline by Corbus Pharmaceuticals Inc, 2022

Diabetic Nephropathy – Pipeline by CSL Ltd, 2022

Diabetic Nephropathy – Pipeline by Curacle Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Daiichi Sankyo Co Ltd, 2022

Diabetic Nephropathy – Pipeline by DiaMedica Therapeutics Inc, 2022

Diabetic Nephropathy – Pipeline by Dimerix Ltd, 2022

Diabetic Nephropathy – Pipeline by Frontbio Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Future Medicine Co Ltd, 2022

Diabetic Nephropathy – Pipeline by GenKyoTex SA, 2022

Diabetic Nephropathy – Pipeline by Gilead Sciences Inc, 2022

Diabetic Nephropathy – Pipeline by Glycadia Inc, 2022

Diabetic Nephropathy – Pipeline by Gmax Biopharm LLC, 2022

Diabetic Nephropathy – Pipeline by GNI Group Ltd, 2022

Diabetic Nephropathy – Pipeline by Goldfinch Bio Inc, 2022

Diabetic Nephropathy – Pipeline by Guangdong East Sunshine Pharmaceutical Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Guangzhou Nanxin Pharmaceutical Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Hua Medicine Shanghai Ltd, 2022

Diabetic Nephropathy – Pipeline by Inovio Pharmaceuticals Inc, 2022

Diabetic Nephropathy – Pipeline by InSilico Medicine, 2022

Diabetic Nephropathy – Pipeline by Inversago Pharma Inc, 2022

Diabetic Nephropathy – Pipeline by Johnson & Johnson, 2022

Diabetic Nephropathy – Pipeline by Landos Biopharma Inc, 2022

Diabetic Nephropathy – Pipeline by MediPost Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Merck & Co Inc, 2022

Diabetic Nephropathy – Pipeline by Mesoblast Ltd, 2022

Diabetic Nephropathy – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022

Diabetic Nephropathy – Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Novartis AG, 2022

Diabetic Nephropathy – Pipeline by Novo Nordisk AS, 2022

Diabetic Nephropathy – Pipeline by Ono Pharmaceutical Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Orbsen Therapeutics Ltd, 2022

Diabetic Nephropathy – Pipeline by PhytoHealth Corp, 2022

Diabetic Nephropathy – Pipeline by Poxel SA, 2022

Diabetic Nephropathy – Pipeline by Praetego Inc, 2022

Diabetic Nephropathy – Pipeline by ProKidney LLC, 2022

Diabetic Nephropathy – Pipeline by RAGE Biotech Pty Ltd, 2022

Diabetic Nephropathy – Pipeline by Reata Pharmaceuticals Inc, 2022

Diabetic Nephropathy – Pipeline by Rebus Holdings Inc, 2022

Diabetic Nephropathy – Pipeline by Scohia Pharma Inc, 2022

Diabetic Nephropathy – Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2022

Diabetic Nephropathy – Pipeline by Serodus ASA, 2022

Diabetic Nephropathy – Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2022

Diabetic Nephropathy – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022

Diabetic Nephropathy – Pipeline by siRNAgen Therapeutics Corp, 2022

Diabetic Nephropathy – Pipeline by Slate Bio Inc, 2022

Diabetic Nephropathy – Pipeline by Sulfateq BV, 2022

Diabetic Nephropathy – Pipeline by Unicyte AG, 2022

Diabetic Nephropathy – Pipeline by Vidasym Inc, 2022

Diabetic Nephropathy – Pipeline by Wuhan Hamilton Bio-technology Co Ltd, 2022

Diabetic Nephropathy – Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022

Diabetic Nephropathy – Pipeline by XORTX Therapeutics Inc, 2022

Diabetic Nephropathy – Pipeline by ZyVersa Therapeutics Inc, 2022

Diabetic Nephropathy – Dormant Projects, 2022

Diabetic Nephropathy – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Diabetic Nephropathy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.